Following a comprehensive assessment of the extended effectivenes and adverse events of four SGLT-2 inhibitors in patients with stage G4 DKD, over a follow-up period ranging from 1.3 to 2.6 years, it has been observed that these medications exhibit reduced efficacy in lowering blood glucose levels in such individuals. Here, SLC5A2 is linked to diabetic kidney disease.